Titlebook: Gallbladder Cancer; Current Treatment Op Vijay Kumar Shukla,Manoj Pandey,Ruhi Dixit Book 2023 The Editor(s) (if applicable) and The Author(

挫敗

Targeted Therapy: Molecular Pathology and Targets of Gallbladder Canceres to occlude the atypical signaling pathway in gallbladder cancer. We also mention the clinical trials associated with combination targeted therapy for gallbladder cancer that may offer favorable therapeutic.

maintenance

Targeted Therapies in Gallbladder Cancer: Current Status and Future PerspectivesERK, PI3K/AKT/mTOR, ErbB1, TP53, HER2, KRAS, VEGF, HIF1, and PTCH1/SMO/GLI1 in gallbladder cancer pathogenesis. Developing an effective targeted therapy by inhibiting these signaling molecules has potential to elevate the treatment efficacy of gallbladder cancer.

不適當(dāng)

公社

Phase II: There is no Alternative!,trials comparing adjuvant chemotherapy versus adjuvant chemoradiation (CRT), the best treatment strategy for high-risk patients is still not established. This chapter summarizes the adjuvant treatment modalities and the evidence supporting the use of adjuvant therapy in GBC.

Monolithic

GULLY

Conventional Therapy in Gallbladder Cancerhe management of the patients will mainly depend on the level of invasion of the tumor in the gallbladder wall. For advanced stage cases, some other procedures are performed such as lymphadenectomy, pancreaticoduodenectomy, palliative, chemotherapy, and radiotherapy.

平常

peak-flow

憲法沒有

Incidental Gallbladder Cancer: The Role of Routine Versus Selective Histopathological Examination ofallbladder, there is an ongoing debate as to whether such a practice should be performed routinely or on a selective basis. This chapter reviews data addressing both strategies. We also report our personal experience on the subject and conclude by providing an evidence-based approach to examining gallbladder specimens.

擦試不掉